Clinical trial

Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II)

Name
GLI.04.SPR.US10330
Description
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
Trial arms
Trial start
2015-05-27
Estimated PCD
2015-09-19
Trial end
2015-09-19
Status
Completed
Treatment
Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Arms:
Treatment
Size
61
Primary endpoint
Change From Baseline in Investigator's Rating of Global Photographs at Week 12
At Week 12
Eligibility criteria
Key Inclusion Criteria: 1. Female patients age 18 to 60 years at the time of enrollment. 2. Women who have self-perceived thinning hair. 3. Women who have presentation of female pattern hair loss/androgenic alopecia (Ludwig I and II). Key Exclusion Criteria: 1. History of allergic reactions or severe intolerance to minoxidil and Botanical Hair Solution product ingredients. 2. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study. 3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume. 4. Any significant history of concurrent medical disease, which in the judgment of the Investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results. 5. Subjects who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study. 6. Pregnant or breast-feeding females or women planning to become pregnant during the course of the study
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 61, 'type': 'ACTUAL'}}
Updated at
2023-08-01

1 organization

1 product

2 indications

Organization
Galderma R&D